Clinical trials: Pheochromocytomas
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pheochromocytoma, Paraganglioma
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
This clinical trial is designed to evaluate the effectiveness and collect additional safety information on AZEDRA® (iobenguane I 131) for the treatment of metastatic or relapsed/refractory (to other treatment) or unresectable…
- Trial name
- NCT00874614
- Testing
- Ultratrace® Iobenguane I131
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Paraganglioma, Pheochromocytoma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer.
- Trial name
- SNIPP (NCT00843037)
- Testing
- Sunitinib
- Where
- 4 sites in Canada, Netherlands
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Neuroendocrine Tumors, Paraganglioma
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Peptide receptor radionuclide therapy (PRRT) may be recommended in G1- G2 GEP-NET patients with disease progression on somatostatine analogues therapy (LUTATHERA®).
- Conditions
- Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
- Trial name
- LUFOR (NCT06045260)
- Testing
- 177Lu-DOTATOC
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Pheochromocytoma, Paraganglioma
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
White adipose tissue (WAT) and brown adipose tissue (BAT) form the main adipose tissue subtypes in humans and several animals. BAT, owing to its unique metabolic function, has been of increased focus and interest in metabolic…
- Trial name
- NCT06440122
- Testing
- FDG-PET Scan
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- King's College Hospital NHS Trust
Adrenal Tumors, Adrenocortical Carcinoma
Adrenal Tumors - Pathogenesis and Therapy
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates…
- Conditions
- Adrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome
- Trial name
- NCT00669266
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Wuerzburg
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Pheochromocytoma, Obstructive Sleep Apnea
Metanephrines in Obstructive Sleep Apnoea
Although most patients have essential (unexplained) hypertension, some patients have a treatable underlying condition. One such condition is phaeochromocytoma, a tumour that produces excessive stress hormones.
- Conditions
- Pheochromocytoma, Obstructive Sleep Apnea, Catecholamine; Secretion
- Trial name
- NCT05053685
- Testing
- Measurement of Urine and plasma metanephrines
- Where
- Singapore
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Neuroblastoma, Pheochromocytoma
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors
- Trial name
- NCT00590096
- Volunteers
- 1,380 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Pheochromocytoma, Paraganglioma
Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma
The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020.
- Trial name
- NCT05451134
- Testing
- Catecholamines
- Where
- China
- Volunteers
- 300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Neuroblastoma, Pheochromocytoma
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
- Trial name
- NCT00107289
- Testing
- iobenguane I 131
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chromaffin-tissue Derived Tumors
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Context. Nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted with specific…
- Trial name
- NCT00875407
- Testing
- Scintigraphy in 123I-IBZM
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Adrenal Tumor
Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.
Context: Adrenalectomy for pheochromocytoma (PHEO) poses difficulties due to the elevated chance of conversion. The objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in…
- Trial name
- NCT06330558
- Testing
- laparoscopic right adrenalectomy
- Volunteers
- 271 people
- Sponsor
- Zagazig University
Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin…
- Conditions
- Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
- Trial name
- NET-COMPARE (NCT07621146)
- Testing
- 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by…
- Conditions
- Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma
- Trial name
- NCT02302833
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.
- Conditions
- Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease, Pheochromocytoma, Paraganglioma
- Trial name
- NCT04891081
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Ljubljana